Reminder for uniQure (QURE) Investors of Securities Class Action by Faruqi & Faruqi, LLP

A deadline is approaching for investors involved in a securities class action against uniQure N.V. The legal firm Faruqi & Faruqi, LLP is leading an investigation into potential claims against the company, urging investors to take action before the April 13, 2026, deadline to seek the lead plaintiff role in the federal securities class action.

The complaint centers around allegations that uniQure and its executives violated federal securities laws by allegedly making false or misleading statements and failing to disclose critical information. Specifically, it is claimed that uniQure’s Pivotal Study design, which included comparing the study results to an external historical data set, did not have full FDA approval. Additionally, the defendants are accused of downplaying the potential need to delay the Biologics License Application (BLA) timeline despite reportedly successful Pivotal Study results. This failure to disclose pertinent information led to statements about the company’s business and prospects lacking a reasonable basis.

In November 2025, uniQure revealed that the FDA no longer agreed that data from the Phase I/II AMT-130 studies would be sufficient to support a BLA submission when compared to an external control, contrary to what was previously communicated to the agency. This admission also included uncertainty surrounding the timing of any BLA submission for AMT-130, contradicting earlier assertions of an accelerated approval trajectory. As a result of this disclosure, uniQure’s stock price plummeted more than 49% from $67.69 on October 31, 2025, to $34.29 on November 3, 2025.

The lead plaintiff in the case represents the investor with the most significant financial stake in the relief sought by the class, embodying qualities typical and adequate to oversee the litigation on the class’s behalf. While any class member can vie for the lead plaintiff role through their chosen legal representation, others may opt to remain passive participants. Participation or lack thereof does not affect the ability to partake in any potential recovery.

Faruqi & Faruqi, LLP invites individuals with insights into uniQure’s conduct to come forward, including whistleblowers, former employees, and shareholders. For more information on the class action against uniQure, visit the Faruqi & Faruqi website or reach out directly to partner Josh Wilson via the provided contact information.

In conclusion, the legal proceedings against uniQure highlight the significance of transparency and adherence to regulatory guidelines in the pharmaceutical industry. Investors are encouraged to take necessary steps to protect their rights and interests in light of the unfolding situation.